Charts

On Friday, 469 companies hit new 52-week lows. Noteworthy Points From Today's 52-Week Lows: The largest company ...

Gainers Bird Global, Inc. (NYSE: BRDS) shares rose 58.7% to $0.2250 in pre-market trading after gaining more than 17% on Thursday. ...

During Wednesday's session, 104 stocks hit new 52-week lows. Facts of Interest About Today's 52-Week ...

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced a corporate restructuring plan to reduce costs and prioritize its pending lead US clinical programs.

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced that the Company has been granted a formal extension to regain compliance under Nasdaq Listing Rule 5550(b)(2) or its alternative criteria. The Company is obligated to meet certain milestones, but has until June 30, 2023 to meet the requirement.

Gainers ThermoGenesis Holdings (NASDAQ:THMO) stock rose 35.6% to $5.68 during Wednesday's after-market session. Trading volume for this ...

Gainers ThermoGenesis Holdings (NASDAQ:THMO) shares rose 78.7% to $3.77 during Wednesday's regular session. As of 13:30 EST, this ...

Gainers ThermoGenesis Holdings, Inc. (NASDAQ: THMO) shares jumped 80% to $3.7820 after the company announced the roll out of ...

Gainers Jounce Therapeutics, Inc. (NASDAQ: JNCE) shares rose 36.8% to $1.45 in pre-market after the company confirmed receipt of ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're beginning the day with a look at the biggest pre-market stock movers traders need to know about for Wednesday morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It

Gainers TScan Therapeutics (NASDAQ:TCRX) shares increased by 28.8% to $3.4 during Tuesday's after-market session. The company's market ...

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced that the company has taken steps to focus its clinical strategy on the planned future FDA trials for TCB-008 in AML as a monotherapy and other oncology indications in combination with additional assets.

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the appointment of Dr. Michael Leek to the position of Chief Technology Officer. Dr. Leek resumes operational duties as CTO after stepping down as executive chairman of the board.

Gainers Ambrx Biopharma (NYSE:AMAM) shares increased by 51.1% to $4.91 during Tuesday's regular session. Ambrx Biopharma's stock is ...

TC BioPharm(Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced today the publication of a paper entitled, "A Phase I trial of allogeneic γδ T lymphocytes from haploidentical donors in patients with refractory or relapsed acute myeloid leukemia" in Clinical Lymphoma, Myeloma and Leukemia, a monthly peer reviewed journal.

TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the appointment of Arlene M. Morris to the position of Chair of the Board.

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced that it now plans to host its shareholder update call on Tuesday, February 21, 2023, at 12:00 p.m. ET. The call was originally scheduled for Monday, February 20, 2023, at 10:00 a.m. ET.

TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the official dosing of its final patient from the safety cohort for ACHIEVE, its phase 2B clinical trial of OmnImmune® (TCB008) for treatment of Acute Myeloid Leukemia (AML).

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the appointment of Bree Harlin as Chief Clinical Officer (CCO), effective immediately.

Gainers Redhill Biopharma (NASDAQ:RDHL) stock rose 35.0% to $0.25 during Friday's pre-market session. The market value of their ...

Gainers MicroAlgo Inc. (NASDAQ: MLGO) shares jumped 74% to $2.90. MicroAlgo recently entered into securities purchase agreement ...

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining over 100 points on Thursday. Following the market opening ...

Upgrades According to Tigress Financial, the prior rating for Walmart Inc (NYSE:WMT) was changed from Neutral to Buy. In the third ...

This week, TC BioPharm Holdings PLC (NASDAQ: TCBP), a clinical-stage biotech working on cutting-edge immunotherapies for some of the ...

Gainers Minerva Surgical (NASDAQ:UTRS) stock moved upwards by 82.4% to $0.69 during Thursday's pre-market session. The company's market ...

Gainers Jeffs' Brands Ltd (NASDAQ: JFBR) rose 76.5% to $2.70 in pre-market trading after jumping 19% on Friday. Pliant ...

Gainers Iterum Therapeutics (NASDAQ:ITRM) shares moved upwards by 8.5% to $1.28 during Friday's after-market session. The company's ...

Gainers Helbiz, Inc. (NASDAQ: HLBZ) shares jumped 133.1% to $0.2870. Helbiz recently announced discontinuation of operations in ...

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the company will host a shareholder update call on Monday, February 20th, 2023, at 10:00 am EST.

U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping around 150 points on Thursday. The Dow traded down ...

Gainers Genius Group Limited (NYSE: GNS) jumped 87% to $1.00. Genius Group authorized issue of special dividend and appointed ...

Gainers BeyondSpring (NASDAQ:BYSI) stock moved upwards by 24.4% to $2.7 during Thursday's regular session. Trading volume for ...

U.S. stocks traded lower midway through trading, with the Dow Jones dropping around 300 points on Thursday. The Dow traded down 0.92% ...

TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), has received written notification from the listing qualifications staff of the Nasdaq Stock Market, LLC ("Nasdaq") indicating that the Company has not regained compliance with the minimum Market Value of Listed Securities ("MVLS") of $35,000,000 required for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(b)(2) (the "MVLS Requirement").

Gainers Tricida, Inc. (NASDAQ: TCDA) rose 37.7% to $0.1898 in pre-market trading after gaining 4% on Wednesday. Huadi ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're starting off Thursday with an overview of the biggest pre-market stock movers traders will want to keep an eye on! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

Gainers Ontrak, Inc. (NASDAQ: OTRK) shares jumped 101.7% to $1.1599 after the company announced new data that shows a reduction in ...

U.S. stocks traded higher this morning, with the Dow Jones gaining around 50 points on Wednesday. Following the market opening ...

Shares of clinical-stage biopharmaceutical companyTC BioPharmPlc (NASDAQ: TCBP) are continuing to trade higher ...

Gainers Ontrak (NASDAQ:OTRK) stock increased by 44.3% to $0.83 during Wednesday's pre-market session. The market value of their ...

Gainers TC BioPharm (Holdings) (NASDAQ:TCBP) stock rose 90.6% to $8.5 during Friday's regular session. As of 12:30 EST, TC BioPharm ...

Gainers BigBear.ai Holdings, Inc. (NYSE: BBAI) shares jumped 239% to $2.8715 after the company announced it has been awarded a ...

U.S. stocks traded lower this morning, following the release of inflation data. Following the market opening Thursday, the Dow traded ...

Although US stocks closed higher on Wednesday, there were a few notable insider trades. When insiders purchase shares, it indicates ...

Gainers Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) shares surged 179.3% to $2.4585 after the company announced that it has ...

Gainers Vyant Bio, Inc. (NASDAQ: VYNT) shares rose 110.4% to $1.62 in pre-market trading after the company said it has engaged ...

TC BioPharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer treatment, today announced its financial results for the first half ended June 30, 2022 and provided a shareholder update.

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (Nasdaq: TCBP) (Nasdaq: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer treatment, today announced the closing of its previously announced private placement for the issuance and sale of 1,470,000 American Depositary Shares (the "ADSs")(or ADS equivalents in lieu thereof), Series A warrants to purchase up to an aggregate of 1,470,000 ADSs and Series B warrants to purch

On Tuesday, 89 companies set new 52-week lows. Noteable 52-Week Lows: The largest company in terms of market cap to ...

U.S. stocks traded lower toward the end of trading amid protests over COVID-19 restrictions in China.The Dow Jones ...

Gainers Taboola.com Ltd. (NASDAQ: TBLA) shares gained 52.5% to $2.8050 after the company announced it entered into a 30-year ...

Gainers NanoVibronix (NASDAQ:NAOV) shares rose 59.9% to $0.41 during Monday's regular session. The current volume of 8.6 million shares ...

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (Nasdaq: TCBP) (Nasdaq: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer treatment, today announced that it has entered into a securities purchase agreement with healthcare-focused and institutional investors for the sale and issuance in a private placement of 1,470,000 American Depositary Shares (the "ADSs")(or ADS equivalents in lieu thereof), Series A warrants to pu

TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer today announced the dosing of its first three patients within its Phase 2b clinical trial of OmnImmune®, an allogeneic unmodified cell therapy focused on treating Acute Myeloid Leukemia (AML).

A look at the shareholders of TC Biopharm (Holdings) Plc ( NASDAQ:TCBP ) can tell us which group is most powerful. We...

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer treatment, today announced the company has completed its scientific advisory board (SAB) to advance new therapeutic trials and establish strategic relationships within the cell therapy sector.

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced that management will be presenting at the Dawson James 7th Annual Small Cap Growth Conference and LD MICRO Main Event XV.

TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer today announced that it has received approval from the UK regulatory body MHRA to apply an 18-month extrapolated shelf life to its current allogeneic cell therapy product, OmnImmune®.